Analyst Price Targets — FTH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 21, 2026 10:03 am | Gil Blum | Needham | $56.00 | $32.10 | TheFly | Faeth Therapeutics initiated with a Buy at Needham |
| July 31, 2026 10:05 am | Sean McCutcheon | Raymond James | $56.00 | $28.82 | StreetInsider | Raymond James Starts Faeth Therapeutics (FTH) at Outperform |
| July 27, 2026 8:29 pm | — | Oppenheimer | $60.00 | $29.24 | TheFly | Faeth Therapeutics initiated with an Outperform at Oppenheimer |
| June 25, 2026 8:15 pm | Jack Allen | Robert W. Baird | $57.00 | $24.67 | TheFly | Faeth Therapeutics initiated with an Outperform at Baird |
| June 22, 2026 10:00 am | — | H.C. Wainwright | $60.00 | $17.82 | TheFly | Faeth Therapeutics initiated with a Buy at H.C. Wainwright |
| May 28, 2026 11:06 am | Christopher Liu | Loop Capital Markets | $50.00 | $16.65 | StreetInsider | Lucid Capital Markets Starts Sensei Biotherapeutics (SNSE) at Buy |
| May 13, 2024 4:20 pm | Sudan Loganathan | Stephens | $5.00 | $1.57 | TheFly | Sensei Biotherapeutics initiated with an Overweight at Stephens |
| December 13, 2022 1:13 pm | — | Citigroup | $6.00 | $1.74 | Benzinga | Citigroup Initiates Coverage On Sensei Biotherapeutics with Buy Rating, Announces Price Target of $6 |
Latest News for FTH
Does Faeth Therapeutics, Inc. (FTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
[url="]Faeth Therapeutics[/url] (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor conferences:Wells Fargo 21st Annual Healthcare ConferenceTuesday, September 8, 20261x1 investor meetingsBoston, MACiti Biopharma Back to School…
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an aggregate of 94,000 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective August 25, 2026, pursuant to the Company's 2026…
The mean of analysts' price targets for Faeth Therapeutics, Inc. (FTH) points to a 72.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FTH.
U.S. House Trading
No House trades found for FTH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.